Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback